Clinical Trial: Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Open Label, Single Dose Study Of The Pharmacokinetics Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

Brief Summary: Open label, single dose study of the pharmacokinetics of tigecycline in adult subjects with primary biliary cirrhosis (PBC)

Detailed Summary: pharmacokinetic study
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Current Primary Outcome: To assess the pharmacokinetics (PK) of tigecycline in subjects with cholestatic hepatic dysfunction. [ Time Frame: 5 days ]

Original Primary Outcome: To assess the pharmacokinetics (PK) of tigecycline in subjects with cholestatic hepatic dysfunction.

Current Secondary Outcome: To assess the safety and tolerability of single doses of tigecycline in subjects with cholestatic hepatic dysfunction. [ Time Frame: 15 days ]

Original Secondary Outcome: To assess the safety and tolerability of single doses of tigecycline in subjects with cholestatic hepatic dysfunction.

Information By: Wyeth is now a wholly owned subsidiary of Pfizer

Dates:
Date Received: November 29, 2006
Date Started: December 2006
Date Completion:
Last Updated: April 1, 2011
Last Verified: April 2011